Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

@article{Baldwin2005EvidencebasedGF,
  title={Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology},
  author={David S. Baldwin and Ian M. Anderson and David J. Nutt and Borwin Bandelow and Alyson J. Bond and Jonathan R. T. Davidson and Johan A. den Boer and Naomi Anne Fineberg and Martin Knapp and Jan Scott and H‐U. Wittchen},
  journal={Journal of Psychopharmacology},
  year={2005},
  volume={19},
  pages={567 - 596}
}
These British Association for Psychopharmacology guidelines cover the range and aims of treatment for anxiety disorders. They are based explicitly on the available evidence and are presented as recommendations to aid clinical decision making in primary and secondary medical care. They may also serve as a source of information for patients and their carers. The recommendations are presented together with a more detailed review of the available evidence. A consensus meeting involving experts in… 

Evidence-based guidelines for treating depressive disorders with antidepressants: A revision of the 2008 British Association for Psychopharmacology guidelines

TLDR
These guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing and management, next-step treatment, relapse prevention, treatment of relapse and stopping treatment.

Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology

This revision of the 2005 British Association for Psychopharmacology guidelines for the evidence-based pharmacological treatment of anxiety disorders provides an update on key steps in diagnosis and

The German guidelines for the treatment of anxiety disorders

A consensus group consisting of 36 experts representing 20 leading German specialist societies and patient self-help organizations developed evidence-based recommendations for the treatment of

British Association for Psychopharmacology consensus statement on evidence-based treatment of insomnia, parasomnias and circadian rhythm disorders

TLDR
These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment.

circadian rhythm disorders British Association for Psychopharmacology consensus statement on evidence-based treatment of

TLDR
These British Association for Psychopharmacology guidelines are designed to address this problem by providing an accessible up-to-date and evidence-based outline of the major issues, especially those relating to reliable diagnosis and appropriate treatment.

The diagnosis of and treatment recommendations for anxiety disorders.

TLDR
It was concluded that anxiety disorders should be treated with psychotherapy, psychopharmacological drugs, or both, and Cognitive behavioral therapy is supported by higher-level evidence than any other psychotherapeutic technique.

A 2010 Evidence-Based Algorithm for the Pharmacotherapy of Social Anxiety Disorder

TLDR
The updated algorithm attempts to summarize succinctly the recent literature in this area, as well as to include the views of an international panel of experts with diverse experience on the pharmacotherapy of social anxiety disorder.

Challenges in the treatment of anxiety disorders: beyond guidelines

  • R. Lam
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2006
TLDR
Optimal treatments for anxiety should be based on chronic disease management and balance efficacy with long-term tolerability, and first-line therapies should include broad-spectrum agents that have proven efficacy in treating both anxiety and depression and are effective across all treatment phases.

Review: A psychopharmacological treatment algorithm for generalised anxiety disorder (GAD)

TLDR
An algorithm for the psychopharmacologic management of GAD is presented, intended for all clinicians who treat patients with GAD, where issues of pharmacotherapy are under consideration, taking into account salient symptomatology and comorbidity, levels of evidence and extent of response.

The new guidelines from the British Association for Psychopharmacology for anxiety disorders

  • I. Anderson
  • Psychology, Medicine
    International journal of psychiatry in clinical practice
  • 2006
TLDR
The British Association for Pharmacology has issued comprehensive evidence-based guidelines to aid clinicians in diagnosing and treating anxiety disorders, and focuses on pharmacological interventions for all primary anxiety disorders in adults (18–65 years).
...

References

SHOWING 1-10 OF 298 REFERENCES

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines

TLDR
The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.

Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 1993 British Association for Psychopharmacology guidelines. British Association for Psychopharmacology.

TLDR
The guidelines cover the nature and detection of depressive disorders, acute treatment with antidepressant drugs, choice of drug versus alternative treatment, practical issues in prescribing, management when initial treatment fails, continuation treatment, maintenance treatment to prevent recurrence and stopping treatment.

Evidence-Based Guidelines for the Pharmacological Management of Substance Misuse, Addiction and Comorbidity: Recommendations from the British Association for Psychopharmacology

TLDR
These guidelines primarily cover the pharmacological management of withdrawal, shortand longterm substitution, maintenance of abstinence and prevention of complications, where appropriate, in substance misuse, addiction and comorbidity with psychiatric disorders.

The evidence-based pharmacological treatment of social anxiety disorder.

TLDR
Based on their efficacy for SAD and common comorbid disorders, tolerability, and safety, SSRIs should be considered as the first-line treatment for most patients, and clinical experience suggests that SSRI non-responders may benefit from augmentation with benzodiazepines or gabapentin, or from switching to MAOIs, RIMAs, Benzodiazepine or gABapentin.

Antipsychotic drugs for non-psychotic patients: assessment of the benefit/risk ratio in generalized anxiety disorder

TLDR
This paper summarizes the evidence from treatment studies of antipsychotic drugs in patients with generalized anxiety disorder (GAD), and compares this with the advice given in major psychiatric textbooks.

International study of expert judgment on therapeutic use of benzodiazepines and other psychotherapeutic medications: VI. Trends in recommendations for the pharmacotherapy of anxiety disorders, 1992–1997

TLDR
This report focuses on the experts' responses to questions about therapeutic options relevant to seven vignettes describing typical cases of different anxiety disorders, as well as on the preferred initial treatment strategy.

Evidence-based pharmacotherapy of Generalized Anxiety Disorder.

TLDR
Due to their efficacy in GAD and comorbid anxiety and depressive disorders, their tolerability and safety, certain selective serotonin re-uptake inhibitors (escitalopram, paroxetine, sertraline) should be considered the first-line treatment for most patients, although the serotonin-noradrenaline re-ptake inhibitor venlafaxine is a reasonable alternative.

[Generalized anxiety disorders in primary medical care].

TLDR
This paper particularly emphasises the standard use of time-efficient diagnostic screening instruments, because improved recognition and diagnosis is the prerequisite for appropriate treatment.

The clinical and cost-effectiveness of self-help treatments for anxiety and depressive disorders in primary care: a systematic review.

  • P. BowerD. RichardsK. Lovell
  • Medicine, Psychology
    The British journal of general practice : the journal of the Royal College of General Practitioners
  • 2001
TLDR
In conclusion, self-help treatments may have the potential to improve the overall cost-effectiveness of mental health service provision, but the available evidence is limited in quantity and quality and more rigorous trials are required to provide more reliable estimates of the clinical and cost-Effectiveness of these treatments.

World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Anxiety, Obsessive-Compulsive and Posttraumatic Stress Disorders

  • B. BandelowJ. ZoharE. HollanderS. KasperH. MöllerWFSBP Task Force on Treatment Guidelines for Anxie
  • Psychology, Medicine
    The world journal of biological psychiatry : the official journal of the World Federation of Societies of Biological Psychiatry
  • 2002
TLDR
Recommendations for the pharmacological treatment of anxiety and obsessive-compulsive disorders are presented, based on available randomized, placebo- or comparator-controlled clinical studies, and SSRIs are recommended for the first line and MAOIs, moclobemide and benzodiazepines as second line.
...